Publications

Machacek M, Renaud L, Wach A, Zwingelstein C, Beni L, Dale GE. 2017. Population pharmacokinetics modeling of murepavidin (POL7080) and simulation of target attainment in a population with ventilator-associated pneumonia due to infection with Pseudomonas aeruginosa, Abstr. 2729. 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25, Vienna, Austria.

Jimmy A Rotolo, Ricardo A. Ramirez, Raymond Schuch, Matthias Machacek, Tatiana Khariton, Parviz Ghahramani, and Michael Wittekind. PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose. ASM Microbe 2016, June 18.

Matthias Machacek, Lionel Renaud, Sasa Dimitrijevic, Debora Schmitz, Elena Ivanova, Karin Jorga. Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors. J Clin Oncol 34, 2016 (suppl; abstr e14101).

Matthias Machacek, Ulrich-Frank Pape, Ulrich Keilholz, Marianne Sinn, Stefan Kasper, Johannes Meiler, Arndt Vogel, Lothar Mueller, Karel Caca, Jan Kuhlmann, Oswald Burkhard, Victor Rodriguez Laval, Glyn Steventon, Nalan Utku, Holger Jansen. Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. J Clin Oncol 34, 2016 (suppl; abstr e15602).